Cargando…

Whether the timing of patient randomization interferes with the assessment of the efficacy of ruxolitinib for severe COVID-19

Detalles Bibliográficos
Autores principales:	Li, Hailan, Liu, Huaping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Academy of Allergy, Asthma & Immunology 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498226/ https://www.ncbi.nlm.nih.gov/pubmed/32980157 http://dx.doi.org/10.1016/j.jaci.2020.09.002

Ejemplares similares

Ruxolitinib and Severe COVID-19
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Ruxolitinib withdrawal due to the COVID-19
por: Lucijanic, Marko, et al.
Publicado: (2021)

Response to: Ruxolitinib withdrawal due to the COVID-19
por: Barbui, Tiziano, et al.
Publicado: (2021)

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19
por: Gozzetti, Alessandro, et al.
Publicado: (2020)

Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib
por: Palandri, Francesca, et al.
Publicado: (2023)

Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity
por: Auteri, Giuseppe, et al.
Publicado: (2022)

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis
por: Palandri, Francesca, et al.
Publicado: (2021)

Interference in scientific research on COVID-19 in Turkey
por: Bayram, Hasan, et al.
Publicado: (2020)

Whether cryosurgery for oral premalignant lesions influences the outcome of malignant transformation
por: Liu, Wei, et al.
Publicado: (2023)

Ruxolitinib in severe COVID-19 Results of a multicenter, prospective, single arm, open-label clinical study to investigate the efficacy and safety of ruxolitinib in patients with COVID-19 and severe acute respiratory syndrome
por: Iastrebner, Marcelo, et al.
Publicado: (2021)

Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
por: Kaloyannidis, Panayotis, et al.
Publicado: (2018)

Successful resolution of hemophagocytic lymphohistiocytosis during the chemotherapy course of acute myelocytic leukemia with ruxolitinib
por: Song, Yue, et al.
Publicado: (2022)

Incorporation of Ruxolitinib in the Management of Refractory/Relapsed Hodgkin Lymphoma: Where Do We Stand?
por: Al Sharie, Ahmed H., et al.
Publicado: (2023)

Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD
por: Liu, Yin, et al.
Publicado: (2022)

Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)
por: Neubauer, Andreas, et al.
Publicado: (2020)

Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib
por: Guglielmelli, Paola, et al.
Publicado: (2021)

Whether to make decisions "on the fly" regarding treatment for SARS-CoV-2 infection()
por: Abril López de Medrano, V., et al.
Publicado: (2020)

Ruxolitinib treatment for bronchiolitis obliterans syndrome following hematopoietic stem cell transplant in a patient with primary hemophagocytic lymphohistiocytosis
por: Meng, Guang-Qiang, et al.
Publicado: (2021)

Lung ultrasound: a valuable tool for assessing COVID-19 patients with different severity
por: Si, Xiang, et al.
Publicado: (2022)

Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
por: Verstovsek, S, et al.
Publicado: (2016)

PB2583: RUXOLITINIB IN SEVERE AND CRITICAL COVID19 REQUIRING CPAP
por: Festuccia, Moreno Benedetto, et al.
Publicado: (2023)

Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib
por: Harrington, Patrick, et al.
Publicado: (2022)

Cardiometabolic Traits, Sepsis, and Severe COVID-19: A Mendelian Randomization Investigation
por: Ponsford, Mark J., et al.
Publicado: (2020)

Ruxolitinib and the Mitigation of Severe COVID-19: A Systematic Review and Meta-analysis
por: Quiros, Jorge R., et al.
Publicado: (2021)

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial
por: Cao, Yang, et al.
Publicado: (2020)

Longitudinal Chest CT Features in Severe/Critical COVID-19 Cases and the Predictive Value of the Initial CT for Mortality
por: Li, Hailan, et al.
Publicado: (2021)

Whether early-stage (N0 neck) oral cancer patients received primary tumor resection without neck dissection benefit from immune checkpoint therapy
por: Liu, Wei, et al.
Publicado: (2023)

Efficacy of noninvasive ventilation in patients with COVID-19
por: Shen, Yanfei, et al.
Publicado: (2022)

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation
por: La Rosée, F., et al.
Publicado: (2020)

On the misuse of “weighted” composite scores: the scoring procedure of the FEED questionnaire does not indicate whether it is necessary to differentiate between the frequency of experiencing an emotion and the desire to eat in response to that emotion in the assessment of emotional eating
por: Meule, Adrian
Publicado: (2021)

Mavrilimumab for severe COVID-19
por: Khan, Adil Rashid, et al.
Publicado: (2020)

Mavrilimumab for severe COVID-19
por: Pourhoseingholi, Mohamad Amin, et al.
Publicado: (2020)

Hypertension and severe COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2023)

Polymorphisms and Severity of COVID-19
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

Mediastinal lymphadenopathy in patients with severe COVID-19
por: Valette, Xavier, et al.
Publicado: (2020)

Prothrombotic phenotype in COVID-19 severe patients
por: Helms, Julie, et al.
Publicado: (2020)

Total body bone mineral density and severe COVID-19: A Mendelian randomization analysis in five age strata
por: Ran, Shu, et al.
Publicado: (2022)

Severe COVID-19 in an Infant with Severe Acute Malnutrition
por: Beniwal, Neetu, et al.
Publicado: (2021)

Ruxolitinib for severe fever with thrombocytopenia syndrome (SFTS)
por: Wen, Sai, et al.
Publicado: (2022)

Challenges in the time of COVID-19
por: Plaat, F.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i7qc910mujfb06vsc12mmsrig8